 | |
| Clinical data | |
|---|---|
| Other names | DPDA;N,N-Di-n-propyldopamine;N,N-Dipropyldopamine;N,N-Di-n-propyl-DA;N,N-Dipropyl-DA |
| Drug class | Dopamine receptor agonist;DopamineD1 andD2-like receptoragonist |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C14H23NO2 |
| Molar mass | 237.343 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Dipropyldopamine (DPDA), also known asN,N-di-n-propyldopamine, is asyntheticdopamine receptor agonist related to thecatecholamineneurotransmitterdopamine which has been used inscientific research.[1][2] It is a dualagonist of both dopamineD1-like andD2-like receptors, with much greaterpotency at dopamineD2 receptors than dopamine itself.[2][3] Unlike dopamine, the drug lacksβ-adrenergic receptor activity and also has weakervasoconstrictor effects.[1]
DPDA produceshypolocomotion across a wide range of doses in rodents.[4][5] It modestly reduces climbing behavior at low doses and markedly enhances it at much high doses.[6] The drug is thought to be resistant tometabolism bymonoamine oxidase (MAO) but to still be susceptible to metabolism bycatecholO-methyltransferase (COMT).[7] It was virtually inactiveorally in rodents.[8] In contrast to dopamine, which isperipherally selective, DPDA can cross theblood–brain barrier and produce effects in thecentral nervous system.[8]
DPDA was first described in thescientific literature by 1977.[9] OtherN,N-dialkylderivatives of dopamine besides DPDA have been studied.[4] In addition,esters of DPDA have been developed and studied.[8]
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byadding missing information. |